The global HPV testing and PAP test market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.96% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 4.4 Billion |
Market Forecast in 2033
|
USD 7.0 Billion |
Market Growth Rate (2025-2033) | 4.96% |
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that causes cancer of the cervix, oropharynx, penis, and vulva. It can be detected with the support of various tests and procedures, such as HPV and Papanicolaou (PAP) test. These assessments comprise microscopic observation of specimens and cervical, head and neck cancer screening. Amongst these, HPV tests are deployed for assessing the presence of human papillomavirus that precede the development of genital warts, whereas PAP tests are used for determining changes in the cell and the presence of abnormal cells in cervices.
The increasing prevalence of cervical cancer, especially amongst the adult demographics. due to presence of papillomavirus is facilitating the need for novel, technologically advanced, and cost-effective HPV and PAP screening, which is one of the major factors primarily driving the market growth. In line with this, the introduction of machine-assisted, plasma- and cell-free deoxyribonucleic acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at the early phase is acting as another growth-inducing factor. This is further supported by the continuous clinical trials, developments, and product launches by key players, such as the easy-to-use home HPV screening test, on account of the sudden outbreak of coronavirus disease (COVID-19) pandemic, is providing them with a competitive edge in the market. Other factors, such as the rapid expansion in the healthcare sector and the numerous favorable initiatives undertaken by the government bodies and the non-governmental organizations (NGOs) for sensitizing people regarding the causes of cervical cancer and the benefits of having HPV and PAP tests are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global HPV testing and PAP test market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on test type, product, application and end user.
Breakup by Test Type:
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc. and Thermo Fisher Scientific Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Test Type, Product, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc. and Thermo Fisher Scientific Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global HPV testing and PAP test market was valued at USD 4.4 Billion in 2024.
We expect the global HPV testing and PAP test market to exhibit a CAGR of 4.96% during 2025-2033.
The increasing prevalence of cervical cancer, along with the introduction of machine-assisted, plasma- and cell-free Deoxyribonucleic Acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at an early phase, is primarily driving the global HPV testing and PAP test market.
The sudden outbreak of the COVID-19 pandemic has led to the continuous clinical trials, developments, and product launches, such as the easy-to-use home HPV screening test, as it allows to combat the spread of the coronavirus infection upon hospital visits and interaction with medical equipment.
Based on the test type, the global HPV testing and PAP test market has been bifurcated into HPV test, pap test, and co-testing. Among these, pap test currently holds the majority of the total market share.
Based on the product, the global HPV testing and PAP test market can be segmented into instruments, consumables, and services. Currently, consumables exhibit a clear dominance in the market.
Based on the application, the global HPV testing and PAP test market has been divided into cervical cancer screening and vaginal cancer screening, where cervical cancer screening currently accounts for the largest market share.
Based on the end user, the global HPV testing and PAP test market can be segregated into hospitals and clinics, laboratories, diagnostic centers, and others. Currently, hospitals and clinics exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global HPV testing and PAP test market include Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc., and Thermo Fisher Scientific Inc.